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Abstract 
Neoadjuvant chemotherapy has become the standard treatment strategy for locally advanced breast cancer. 
Currently, neoadjuvant chemotherapy was applied empirically; there are no conventional biomarkers that allow 
for predicting clinical response and benefit from a particular chemotherapy regimen. Studies mention that grade 
and intrinsic subtypes are predictors for clinical response to chemotherapy. Purpose of this study were to know 
the relationship of grade, intrinsic subtype, and clinical response to neoadjuvant chemotherapy in breast cancer. 
Cross-sectional studies by examining breast cancer patients who underwent chemotherapy in Wahidin 
Sudirohusodo,  a top referral hospital with 913 bed in Makassar Indonesia, from January 2015 to December 
2016. Results: During the periods, neoadjuvant chemotherapy have been conducted to 119 breast cancer 
patients. In the bivariate analysis, we found that grade significantly associated with chemotherapy response 
obtained p-value = 0.002 (p < 0.005). Clinical response to neoadjuvant chemotherapy based on subtypes was 
Luminal A 55.2%, Luminal B 61.2 %, Her2 80%, Triple Negative 87.5%. Association of subtype and 
chemotherapy response was also significant with p-value = 0.056. Conclusion: histopathological grading and 
Intrinsic subtype were associated with anthracycline-based neoadjuvant chemotherapy response on breast 
cancer.   
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1. Introduction 
Breast cancer is one of the most common cancers suffered by women across the globe. It accounts for about 
23% of all malignancy in women, and every year 1.1 million women are diagnosed with breast cancer [1].   
In the USA, it is estimated that 192.370 new invasive breast cancer cases and 62.280 in situ breast cancer cases 
are diagnosed each year.  
Mean breast cancer patients age is 61 year with incidence rate 124 per 100.000 women per year [2]. In 
Indonesia, breast cancer is the most common cancer found, followed by cervical cancer. On 2012 breast cancer 
incidence rate in Indonesia was estimated about 48.998 [3].  
According to Jakarta cancer registry, breast cancer has the highest incidence rate in Indonesia with 18.6 per 
100.000 population per year [4]. In 2013, the death rate due to breast cancer in Indonesia was approximately 
19.750 [3].  
Breast cancer treatment consists of surgery, radiotherapy, chemotherapy, and hormonal therapy[5, 6]. 
Chemotherapy is a type of treatment which uses drug combination to destroy or slow down cancer cell 
growth[7, 8]. Today chemotherapy is the most critical component in breast cancer treatment[9, 10].  
Neoadjuvant chemotherapy has become the standard for local breast cancer treatment, and treatment of choice 
for early stage operable breast cancer. Neoadjuvant chemotherapy has much profits for breast cancer treatment, 
which can give the better operative option and better chemotherapy response[11]. 
2. Materials and Method 
2.1. Collection of Samples 
This is an observational study using the longitudinal method to assess the relationship between ER, PR, HER2, 
and the Ki-67 expression on women who suffered locally advanced breast cancer.  
This research was conducted in Dr. Wahidin Sudirohusodo General Hospital, Makassar, South Sulawesi. The 
study period was from December 2015 until December 2016.  
The study subject was all women suffered from locally advanced breast cancer (III-B) who underwent treatment 
in Dr. Wahidin Sudirohusodo General Hospital.  
2.2. Expression DUSP4 by Immunohistochemistry 
ER, PR, HER2, and Ki-67 expression examination were conducted in Pathological Anatomy Laboratory, 
Medical Faculty of Hasanuddin University, Makassar. 
2.3. Classification of clinical response to chemotherapy 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2018) Volume 37, No  1, pp 34-42 
 
36 
 
Chemotherapy response is classified as nonresponsive, if tumor size is reduced ≤ 30%, no change or increased 
in tumor size, or if found a new tumor; while responsive, if tumor is disappear, or there is a reduction >30% and 
no new tumor found.  
2.4. Data Analysis 
Data analysis using the SPSS (Statistical Package for Social Science) version 22. Analysis of patient’s 
characteristics and clinical response using chi square.  
2.5. Ethical Clearence 
Ethical approval for this study was obtained from Research Ethics Committee, Faculty of Medicine, Hasanuddin 
University, Makassar, Indonesia.  
3. Results 
During the study period from December 2015 until December 2016, we collect breast cancer patient’s data who 
had undergone neoadjuvant chemotherapy in Oncology Surgery Division, dr. Wahidin Sudirohusodo General 
Hospital.  
Makassar, and we found 119 sample who met the inclusion criteria, in which 80 patients (67.2 %) responsive to 
neoadjuvant chemotherapy, and 39 (32.8 %) nonresponsive patients.  
3.1. Characteristics 
In this study we found 119 patient who had breast cancer, the youngest being 29 years old, and the oldest is 75 
years old, 74 (62.2%) of them aged < 50 years old. From histopathological grading, we found 10 cases (8.4%) 
low grade, 76 cases (63.9%) average grade, and 33 (27.7%) high grade.  
From immunohistochemical panel, we found 74 (62.2%) ER+, 60 (50.4%) PR+, 59 (49.6%) Her2+, and 
57(47.9%) Ki-67+. From that immunohistochemical panel result, we also found 29 (24.4%) luminal A subtype, 
49 (41.2%) luminal B subtype, 25 (21%) Her2, and 16 (13.4%) triple negative.  
Eighty patients (67.2%) were responsive to the neoadjuvant chemotherapy given.  Characteristics of the breast 
cancer patients can be seen in Table 1 below.  
3.2. Relationship between age and neoadjuvant chemotherapy response on breast cancer 
In this study, we analyze the effect of various clinicopathologic factors toward neoadjuvant chemotherapy 
response on breast cancer because some of those clinicopathologic factors are also confounding factors which 
influence dependent and independent variable.  
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Table 1: Characteristics of breast cancer patients who underwent neoadjuvant chemotherapy 
Characteristics Total (%) 
AGE  
≤ 50 74 (62,2%) 
> 50 45 (37,8%) 
GRADE  
Low Grade 10 (8,4%) 
Moderate Grade  76 (63,9%) 
High Grade  33 (27,7%) 
STADIUM 
I     0 (0%) 
II    0 (0%) 
III A  11 (9,3%) 
III B 108 (90,7%) 
IV      0 (0%) 
HISTOPATHOLOGY  
IDC     109 (91,5%) 
ILC 7 (5,8%) 
Adenoca musinosum 1 (0,8%) 
Adenoca papiler 1 (0,8%) 
Adenoca meduler 1 (0,8%) 
IMMUNOHISTOCHEMICAL  
ER 74 (62,2%) 
PR 60 (50,4%) 
HER2 59 (49,6%) 
Ki-67 57 (47,9%) 
SUBTYPE  
Luminal A 29 (24,4%) 
Luminal B 49 (41,2%) 
Her2               25 (21%) 
Triple Negative 16 (13,4%) 
REGIMENT ( NEO & ADJUVANT) 
CAF/CEF      89 (74,7%) 
TAC      22 (18,4%) 
TA/TE     9 (7,5%) 
CHEMOTHERAPY RESPONSE  
Responsive 80 (67,2%) 
Nonresponsive 39 (32,8%) 
Table 2: Relationship between Age and Chemotherapy Response on Breast Cancer 
AGE 
Chemotherapy Response 
Total 
Responsive Nonresponsive 
             ≤ 50 48 (64,9%) 26 (35,1%) 74 (100%) 
> 50       32 (71,1%)        13 (28,9%)        45 (100%) 
Total        80 (67,2%)        39 (32,8%)       119 (100%) 
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4. Relationship between grading and neoadjuvant chemotherapy response on breast cancer  
To assess whether grading has correlation with anthracycline-based neoadjuvant chemotherapy response on 
breast cancer, we use bivariate analysis as can be seen in table 3.  
Table 3: Relationship between Grading and Chemotherapy Response On Breast Cancer 
Grading Chemotherapy Response Total 
Responsive Nonresponsive 
Low Grade       2 (20%)          8 (80%)         10 (100%) 
Moderate Grade       51 (67,1%)        25(32,9%)        76 (100%) 
High Grade 27 (81,8%) 6 (18,2%) 33 (100%) 
Total        80 (67,2%)        39 (32,8%)        119 (100%) 
chi-square X2 =  10,619         df = 1           p = 0,001 (p > 0,05) 
Grading analysis, we found that there’s chemotherapy response difference between each grade: 10 (8.4%) on 
low grade, 76 (63.9%) moderate grade, and 33 (27.7%) high grade on breast cancer patients who show 
responsiveness for anthracycline-based neoadjuvant chemotherapy, with p-value = 0.001 (p > 0.05).  So it can 
be said that grading is a predictive factor for anthracycline-based neoadjuvant chemotherapy response.  
5.  Intrinsic Subtype Profile and Neoadjuvant Chemotherapy Response on Breast Cancer 
To find out whether intrinsic subtype has correlation with anthracycline-based neoadjuvant chemotherapy 
response on breast cancer, we used bivariate analysis as can be seen in table 4.  
Table 4: Relationship between Subtype and Chemotherapy Response on Breast Cancer 
Subtype 
Chemotherapy Response 
Total 
Responsive Nonresponsive 
Luminal A       16 (55,2%)          13 (44,8%)         29 (100%) 
Luminal B       30 (61,2%)        19 (38,8%)        49 (100%) 
Her2 20 (80%) 5 (20%) 25 (100%) 
Triple Negative 14 (87,5%) 2 (12,5%) 16 (100%) 
Total        80 (67,2%)        39 (32,8%)        119 (100%) 
chi-square X2 =  7,014         df = 1           p = 0,008 (p > 0,05) 
Subtype have a great impact on chemotherapy responsiveness on breast cancer. From that data we found 16 
(55.2%) luminal A responsive, 30 (61.2%) luminal B responsive, 20 (80%) HER2 responsive, and 14 (87.5%) 
triple negative. Statistically, there has been a significant difference between each subtype on breast cancer 
chemotherapy response with p-value = 0.008 (p > 0.05).  
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4. Discussion 
Studies about biomarkers in relation to chemotherapy response in breast cancer are the primary concern in our 
center as mostly the patients came in advanced stages. The previous research found expression of Ki-67 were 
related to neoadjuvant chemotherapy response [12]. While expression of BCL-2, ER and PgP have an 
insignificant correlation with chemotherapy response in breast cancer [13] [14]. Overexpression of DUSP4 
tends to responsive to neoadjuvant chemotherapy but statistically insignificant [15]. 
From this study we found different age, the youngest being 29 years old, the oldest being 75 years old, median 
46 years old, and 74 (62.2%) aged < 50 years old.  Globally, 33% breast cancer patient was aged < 50 years, 
42% in the Asia Pacific, 47% South East Asian, and 21% Australia. SEER data from the USA shows that most 
of the breast cancer patients were aged 55 – 64 years old with median 61 years old [2]. 
In this study we found; 8.4% low grade, 63.9 % moderate grade, and 27.7% high grade. From chi-square 
analysis we found p-value = 0.001 (p > 0.05), it means that grading is a predictive factor for anthracycline-
based neoadjuvant chemotherapy response.  
Histopathological grading is an already well known prognostic factor. Various new research has confirmed 
histopathological grading importance as a prognostic and predictive factor on breast cancer. Engstrøm and his 
colleagues found that during the first five years, grade 2 and grade 3 breast cancer have a worse prognosis 
compared with grade 1 breast cancer [16].  
Grading is also an independent factor to predict pCR for luminal tumor, clinical tumor staging for HER2 like-
tumor, and age for triple-negative tumor. Grading can give independent information about the clinical response 
for triple negative tumor group. Grading and age can identify subtype on luminal and triple-negative patients 
who will have benefit from NACT [17]. 
From 119 samples which underwent immunohistochemical examination, we found 24.4 % luminal A, 41.2 % 
luminal B, 21% HER2, and 13.4% triple negative. Minhao and his colleagues (2010) research found 19.6% 
luminal A, 22.5% luminal B, 17.6% HER2, and 40.2% triple negative.  Cong Xue and his colleagues (2012) 
who assessed 5806 breast cancer patients in China, described the distribution of 31.1% luminal A, 30.4% 
luminal B, 13.1 % HER2+, 9% HER2, and 5% triple negative. Carol Parise (2014) research data from 143.333 
breast cancer patients consist of 71.778 (50%) luminal A cases, 19.011 (13.3%) luminal B / HER2- cases, 
19.017 (13.3%) luminal B / HER2+ cases, 9.792 (6.8%) HER2+ cases, and 18.724 (13%) triple negative cases. 
Reina Haque (2011) research described that the most common breast cancer subtype is luminal A (66%), 
followed by basal-like (22%), HER2 (7%), and luminal B (5%).  
Subtype plays a critical role in chemotherapy response. From our research data, we found 55.2% responsive 
luminal A subtype, 61.2% luminal B responsive subtype, 80% HER2 responsive subtype, and 87.5% triple 
negative responsive subtype. From statistical analysis, we found a significant difference between various 
subtype with neoadjuvant chemotherapy response on breast cancer with p-value = 0.008 (p >0.05). 
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A previous report in Wahidin Sudirohusodo hospital in 2014, conducted in 247 breast cancer patients,  
Chemotherapy response by subtype were in Luminal subtype responsive 67%,  Her2 responsive  70%, Triple 
Negative responsive 88% [18]. 
Neoadjuvant chemotherapy for breast cancer allows tumor response assessment on various intrinsic subtype. 
ER, PR and HER2 status on breast cancer are important markers for choosing the best chemotherapy drug[19-
21].  
Rouzier research found that complete pathologic response (pCR) on basal-like subtype about 45%, HER2 45%, 
while luminal only have 6% pCR rate. There’s no pCR for the normal-like subtype. Basal-like and HER2 breast 
cancer subtype are more sensitive to adjuvant chemotherapy containing paclitaxel and doxorubicin compared 
with luminal and normal-like subtype [21]. 
5. Conclusion 
This study found that histopathological grading and Intrinsic subtype were significantly associated with 
anthracycline-based neoadjuvant chemotherapy response on breast cancer.  Thus, histopathological grading and 
intrinsic subtype are predictive factors for chemotherapy response on breast cancer. 
6. Recommendation 
 Histopathological grade and intrinsik subtype to be considered for choosing chemotherapy regimen in breast 
cancer. 
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